Table 1.
Patient | Age | Sex | Race | Type of malignancy | Cancer therapy | Rheumatic IRAE | Best overall response (RECIST 1.1) |
---|---|---|---|---|---|---|---|
1 | 58 | Male | Caucasian | Renal cell carcinoma | Anti-PD-1 Anti-CTLA-4 |
Inflammatory arthritis | Stable disease |
2 | 46 | Female | Caucasian | Melanoma | Anti-PD-1 Anti-CTLA-4 |
Inflammatory arthritis | Partial response |
3 | 62 | Male | African American | Non-small cell lung cancer | Anti-PD-1 Anti-CTLA-4 |
Inflammatory arthritis | Stable disease |
4 | 35 | Male | Caucasian | Melanoma | Anti-PD-1 Anti-CTLA-4 |
Inflammatory arthritis | Stable disease |
5 | 56 | Male | Caucasian | Non-small cell lung cancer | Anti-PD-1 | Inflammatory arthritis | Stable disease |
6 | 66 | Male | Caucasian | Melanoma | Anti-PD-1 Anti-CTLA-4 |
Inflammatory arthritis | Partial response |
7 | 57 | Male | Caucasian | Small cell lung cancer | Anti-PD-1 Anti-CTLA-4 |
Inflammatory arthritis | Partial response |
8 | 42 | Male | Caucasian | Non-small cell lung cancer | Anti-PD-1 Anti-CTLA-4 |
Inflammatory arthritis | Partial response |
9 | 75 | Female | Caucasian | Non-small cell lung cancer | Anti-PD-1 | Inflammatory arthritis | Partial response |
10 | 61 | Male | Caucasian | Non-small cell lung cancer | Anti-PD-1 | Sicca syndrome | Stable disease |
11 | 57 | Male | Caucasian | Melanoma | Anti-PD-1 Anti-CTLA-4 |
Sicca syndrome | Progressive disease |
12 | 74 | Male | Caucasian | Melanoma | Anti-CTLA-4 | Sicca syndrome | Partial response |
13 | 74 | Female | Caucasian | Melanoma | Anti-PD-1 | Sicca syndrome | No measureable disease by RECIST; tumour regression observed on clinical exam |
Age is at the time of initial rheumatological assessment.
CTLA-4, cytotoxic T-lymphocyte-associated protein 4; PD-1, programmed cell death protein 1.